派格生物医药-B就申请建议实行H股全流通向中国证监会备案

Core Viewpoint - The company has submitted an application to the China Securities Regulatory Commission to convert a total of 102 million unlisted shares held by 20 shareholders into H-shares on a one-to-one basis, which represents approximately 26.35% of the company's total issued shares as of the announcement date [1] Group 1 - The conversion of unlisted shares into H-shares is aimed at increasing liquidity and potentially enhancing shareholder value [1] - The application to the regulatory body indicates the company's strategic move towards expanding its capital market presence [1] - The conversion process reflects the company's ongoing efforts to align with market practices and improve its financial structure [1]